Welcome to our dedicated page for Tandem Diabetes SEC filings (Ticker: TNDM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tandem Diabetes Care filings document the company’s insulin delivery business, Nasdaq-listed common stock, operating results, governance matters, and capital structure. Recent 8-K reports furnish quarterly and annual financial results, guidance-related disclosures, and product or regulatory events tied to its diabetes technology portfolio.
The filing record also includes proxy materials for annual meeting voting, director elections, executive compensation, equity awards, and board committee matters. Material-event filings describe the company’s completed 0.00% convertible senior notes offering, related indenture terms, and FDA clearance for the SteadiSet wearable infusion set.
Tandem Diabetes Care Inc. (TNDM) reported equity compensation activity for an executive officer. The EVP & Chief Administrative Officer had restricted stock units (RSUs) convert into common stock on 11/17/2025, with 1,503 and 1,096 RSUs settled into shares at an exercise price of $0.
To cover tax withholding on these vestings, the company withheld 430 and 314 shares at a price of $18.61 per share, and no shares were sold into the market. Following these transactions, the reporting person directly beneficially owned around forty thousand shares of Tandem Diabetes Care common stock.
Tandem Diabetes Care Inc. (TNDM) reported insider equity activity by President & CEO and director John F. Sheridan. On 11/17/2025, restricted stock units (RSUs) granted under the company’s 2023 Long-Term Incentive Plan vested and were settled into common stock at no exercise price.
Following the vesting, 5,472 RSUs and 5,982 RSUs were converted into an equal number of common shares. To cover tax withholding on these RSU vestings, the company withheld 2,779 shares and 3,038 shares at a reference price of $18.61 per share; the filing states that no shares were sold. After these transactions, Sheridan directly owned 117,600 shares of common stock, plus 10,943 RSUs and 35,894 RSUs that remain outstanding and subject to the plan’s vesting schedule.
Tandem Diabetes Care (TNDM) executive vice president and chief strategy officer Elizabeth A. Gasser reported several equity transactions in the company’s stock. She voluntarily disclosed acquiring 586 shares of common stock at $15.59 through the company’s Employee Stock Purchase Plan for the May 16, 2025 to November 17, 2025 purchase period.
On the same date, 1,503 and 1,096 shares of common stock were delivered upon the vesting of previously granted restricted stock units, at an exercise price of $0. To cover tax withholding on these RSU vestings, the company withheld 805 and 587 shares at a price of $18.61 per share; no shares were sold into the market.
Following these transactions, Gasser directly beneficially owns 3,000 shares of Tandem Diabetes Care common stock and indirectly beneficially owns 22,949 shares through The Gasser Family Trust dated September 1, 2011, where she serves as co-trustee. The RSUs were granted under the company’s 2023 Long-Term Incentive Plan and vest over multi-year schedules.
Tandem Diabetes Care (TNDM) Chief Technology Officer Rick A. Carpenter reported several equity transactions involving company stock. He voluntarily disclosed acquiring 339 shares of common stock at $15.59 per share through the company’s Employee Stock Purchase Plan for the period from May 16, 2025 through November 17, 2025.
On the same date, 1,437 and 897 restricted stock units (RSUs) were converted into common shares at a $0 exercise price under the 2023 Long-Term Incentive Plan. To cover taxes on these RSU vestings, the company withheld 730 and 456 shares at a price of $18.61 per share, with no shares sold on the market. After these transactions, Carpenter directly beneficially owned 24,053 shares of Tandem Diabetes Care common stock.
Tandem Diabetes Care Inc. (TNDM) reported an insider equity transaction by its EVP & Chief Commercial Officer on a Form 4. On 11/17/2025, 76 restricted stock units (RSUs) were converted to common stock at an exercise price of $0, and 40 shares of common stock were withheld at $18.61 per share to cover tax obligations, with no shares sold on the market. Following these transactions, the officer beneficially owned 32,384 shares of common stock directly and 457 RSUs, subject to the company’s 2023 Long-Term Incentive Plan and a vesting schedule that runs in quarterly installments after an initial vesting on 5/15/2025.
Tandem Diabetes Care, Inc. (TNDM) executive vice president and chief operating officer Jean-Claude Kyrillos reported a routine purchase of company stock. On 11/17/2025, he acquired 160 shares of common stock at a price of $15.59 per share through the Tandem Diabetes Care Inc. Amended and Restated 2013 Employee Stock Purchase Plan for the ESPP purchase period from May 16, 2025 through November 17, 2025. Following this transaction, he beneficially owned 22,544 shares of Tandem Diabetes Care common stock held directly. The transaction is reported as exempt under Rule 16b-3(c), which typically covers certain employee benefit plan-related acquisitions.
Tandem Diabetes Care Inc. (TNDM) reported an insider equity transaction by EVP & Chief Financial Officer Leigh Vosseller on 11/17/2025. The filing shows the exercise of restricted stock units (RSUs), converting 1,503 and 1,496 RSUs into common shares at an exercise price of $0.
To cover tax withholding on these vestings, the company withheld 538 and 536 shares at a price of $18.61 per share, with no open-market sales taking place. After these transactions, Vosseller directly owned 37,648 shares of common stock and an additional 25,580 shares indirectly through the Leigh A. Vosseller Trust.
The Form 4 also notes remaining RSU awards under the company’s 2023 Long-Term Incentive Plan, which continue to vest over time based on previously established schedules.
Tandem Diabetes Care Inc. (TNDM) executive vice president and chief legal officer Shannon M. Hansen reported multiple equity transactions dated 11/17/2025 on a Form 4. Hansen voluntarily reported acquiring 800 shares of common stock through the company’s employee stock purchase plan for the May 16, 2025 to November 17, 2025 purchase period, a transaction noted as exempt under Rule 16b-3(c). Several restricted stock unit (RSU) awards were converted to common stock at a $0 exercise price, while 190, 515 and 393 shares were withheld by the company at $18.61 per share to cover tax obligations, with no market sales. After these transactions, Hansen directly holds 21,474 shares and indirectly holds 1,935 shares through the Shannon M. Hansen Trust.
Tandem Diabetes Care (TNDM) expanded its Board to nine directors and appointed Sandra Beaver effective November 7, 2025, with her term expiring at the 2026 Annual Meeting. She joins the Audit Committee and the Cybersecurity and Data Privacy Committee. Under the company’s director compensation policy, Ms. Beaver received an initial RSU award of 20,242 shares (valued at $300,000) vesting one-third annually. She is eligible for annual cash retainers of $60,000 for Board service, plus $11,000 and $6,000 for the two committees, and an annual RSU around $180,000.
Tandem Diabetes Care reported Q3 2025 results. Sales were $249.3 million, up slightly year over year, with gross profit of $134.3 million. Operating loss was $22.9 million, and net loss narrowed to $21.2 million (basic and diluted loss per share $0.31) from $23.3 million a year ago.
For the first nine months, sales reached $724.4 million and net loss was $204.1 million, reflecting $75.2 million of acquired in‑process R&D, $20.0 million of litigation and settlement expense, and $9.6 million of equity‑method losses. Cash and cash equivalents were $91.9 million and short‑term investments were $227.2 million. Long‑term convertible notes, net, were $309.6 million, and stockholders’ equity was $133.0 million.
Operating cash flow was a use of $19.5 million year‑to‑date, with $87.9 million provided by investing activities and $46.0 million used in financing, including $40.8 million to settle the 2025 notes. The company entered a cross‑license with Roche, agreeing to pay $36.0 million over four years; $13.3 million was capitalized as an intangible asset, and a $31.6 million present‑value liability was recorded. As of November 4, 2025, shares outstanding were 67,802,359.